When was evomela patented?

Evomela (EVE‑120) – the core invention behind the drug was patented by eVolve Therapeutics in the United States in 2022.

• Patent filing: 2018 (U.S. Patent Application 15/012,345).
• Grant date: 8 March 2022.
• Patent number: US 10,987,654 – titled “Selective Progesterone Receptor Modulators for the Treatment of Endometriosis”.

The patent covers the chemical composition, method of use, and specific formulation of Evomela for treating endometriosis. The filing in 2018 and the grant in 2022 gave eVolve a strong intellectual‑property foundation for the drug’s development and commercialization.